Thermo Fisher Scientific HLA-DQA1 Polyclonal Antibody

Applications and Tested Dilution

Product Specifications

Product Specific Information

This antibody detects endogenous levels of total HLA-DQA1.

Target Information

HLA-DQA1 binds peptides derived from antigens that access the endocytic route of antigen-presenting cells (APCs) and presents them on the cell surface for recognition by CD4 T-cells. The peptide binding cleft accommodates peptides of 10–30 residues. Peptides presented by MHC class II molecules are typically generated by degradation of proteins in the endocytic pathway, processed by lysosomal proteases and hydrolases. Exogenous antigens endocytosed by APCs are presented via MHC II molecules, commonly referred to as the exogenous antigen presentation pathway.

Membrane proteins destined for lysosomal degradation also contribute endogenous peptides competing with exogenous ones. Autophagy additionally provides endogenous peptides, as autophagosomes fuse with MHC class II loading compartments. In the gastrointestinal tract, epithelial cells can express MHC class II molecules and CD74, acting as APCs.

MHC class II molecules form heterodimers (α and β chains) that associate with a CD74 trimer in the ER to form a heterononamer complex. During endosomal processing, CD74 is degraded, leaving the CLIP fragment, which is then removed by HLA-DM to allow antigenic peptide binding. HLA-DM stabilizes MHC II until high-affinity peptides bind, after which the complex is transported to the cell surface. HLA-DO regulates HLA-DM interaction in B-cells and dendritic cells. Lysosomal acidification enhances proteolysis and efficient peptide loading.

HLA and MHC antibodies are critical in immunopeptidomics, aiding in the identification and characterization of neoantigens via LC-MS/MS.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.